|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-11-25
|
|
pubmed:abstractText |
This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1478-6362
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
R169
|
|
pubmed:meshHeading |
pubmed-meshheading:20831776-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20831776-Antirheumatic Agents,
pubmed-meshheading:20831776-Arthritis, Rheumatoid,
pubmed-meshheading:20831776-Belgium,
pubmed-meshheading:20831776-Female,
pubmed-meshheading:20831776-Humans,
pubmed-meshheading:20831776-Male,
pubmed-meshheading:20831776-Middle Aged,
pubmed-meshheading:20831776-Registries,
pubmed-meshheading:20831776-Severity of Illness Index,
pubmed-meshheading:20831776-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies.
|
|
pubmed:affiliation |
Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Bert.VanderCruyssen@Ugent.be.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
